Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20(s)-ginsenoside Rg3 in vivo

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 8, 2012, Pages 425-436

  Yang, Lei Qiong ^a   Wang, Bin ^a   Gan, Hui ^a   Fu, Shou Ting ^b   Zhu, Xiao Xia ^a   Wu, Zhuo Na ^a   Zhan, Da Wei ^c   Gu, Ruo Lan ^a   Dou, Gui Fang ^a   Meng, Zhi Yun ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c 304TH HOSPITAL   (China)

Author keywords

20(s) ginsenoside Rg3; anti tumour effect; bioavailability; Caco 2 transport; paclitaxel

Indexed keywords

20(S) GINSENOSIDE RG 3; ANTINEOPLASTIC AGENT; GINSENOSIDE RG 3; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASSAY; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CELL STRAIN MCF 7; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; FEMALE; HUMAN; HUMAN CELL; INCUBATION TEMPERATURE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GINSENOSIDES; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867897025     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1806     Document Type: Article

References (45)

1. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT,. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325-2327.
2. Kumar N,. Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 1981; 256: 10435-10441.
3. Manfedi JJ, Horwitz SB,. An antimitotic agent with a new mechanism of action. Pharmacol Ther 1984; 25: 83-125.
4. Rowinsky EK, Wright M, Monsarrat B, Lesser GJ, Donehower RC,. Taxol: pharmacology, metabolism and clinical implications. Cancer Surv 1993; 17: 283-304.
5. Sarosy G, Kohn E, Stone DA, et al,. Phase I study of taxol and granulocyte stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10: 1165-1170.
6. Wenk MR, Fahr A, Reszka R, Seelig J,. Paclitaxel partitioning into lipid bilayers. J Pharm Sci 1996; 85: 228-231.
7. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC,. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993; 20: 1-15.
8. Varma MVS, Panchagnula R,. Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 2005; 25: 445-453.
9. Theis JG, Liau-Chu M, Chan HS, Doyle J, Greenberg ML, Koren G,. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. J Clin Oncol 1995; 13: 2508-2516.
10. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM,. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994; 54: 4026-4035.
11. Bardelmeijer HA, Beijnen JH, Brouwer KR, et al,. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 2000; 6: 4416-4421.
12. Sparreboom A, van Asperen J, Mayer U, et al,. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 4: 2031-2035.
13. Choi JS, Li X,. The effect of verapamil on the pharmacokinetics of paclitaxel in rats. Eur J Pharm Sci 2005; 24: 95-100.
14. Berg SL, Tolcher A, O'Shaughnessy JA, et al,. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 1995; 13: 2039-2042.
15. Boniface RG, Ferry D, Atsmon J, et al,. XR9576 (tariquidar), a potent and specific P-glycoprotein inhibitor, has minimal effects on the pharmacokinetics of paclitaxel, doxorubicin, and vinorelbine and can be administered with full-dose chemotherapy in patients with cancer. Proc Am Soc Clin Oncol 2002; 21: 2002 (abstr 2173).
16. Woo JS, Lee CH, Shim CK, Hwang SJ,. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res 2003; 20: 24-32.
17. Palmeira A, Sousa E, Vasconcelos M, Pinto M,. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem 2012; 19: 1946-2025.
18. Ryan DP, Kulke MH, Fuchs CS, et al,. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002; 94: 97-103.
19. Gillis CN,. Panax ginseng pharmacology: a nitric oxide link? Biochem Pharmacol 1997; 54: 1-8.
20. + channel inhibition. Mol Cells 2005; 19: 137-142.
21. Mabuchi S, Ohmichi M, Nishio Y, et al,. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res 2004; 15: 7645-7654.
22. Keum YS, Han SS, Chun KS, et al,. Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-kappaB activation and tumor promotion. Mutat Res 2003; 523-524: 75-85.
23. Yamaguchi K, Murai T, Yabuuchi H, Kurosawa T,. Measurement of the transport activities of bile salt export pump using LC-MS. Anal Sci 2009; 25: 1155-1158.
24. Hossain Z, Takahashi K,. Induction of permeability and apoptosis in colon cancer cell line with chitosan. J Food Drug Anal 2008; 16: 1-8.
25. Dintaman JM, Silverman JA,. Inhibition of P-glycoprotein by d -alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999; 16: 1550-1556.
26. Ho PY, Yeh TK, Yao HT, et al,. Enhanced oral bioavailability of paclitaxel by d -α-tocopheryl polyethylene glycol 400 succinate in mice. Int J Pharm 2008; 359: 174-181.
27. Choi JS, Choi HK, Shin SC,. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int J Pharm 2004; 275: 165-170.
28. van Asperen J, van Tellingen O, Sparreboom A, et al,. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 1997; 76: 1181-1183.
29. Kwak JO, Lee SH, Lee GS, et al,. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol 2010; 627: 92-98.
30. Tamura T, Fujita F, Tanimoto M, et al,. Anti-tumor effect of intraperitoneal administration of cisplatin loaded microspheres to human tumor xenografted nude mice. J Control Rel 2002; 80: 295-307.
31. Kimura Y, Aoki J, Kohno M, Ooka H, Tsuruo T, Nakanishi O,. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother Pharmacol 2002; 49: 322-328.
32. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW,. Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994; 54: 5543-5546.
33. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV,. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995; 275: 566-575.
34. Kim SW, Kwon H, Chi DW, Shim JH,. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg3. Biochem Pharmacol 2003; 65: 75-82.
35. Nerurkar MM, Ho NF, Burton PS, Vidmar TJ, Borchardt RT,. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J Pharm Sci 1997; 86: 813-821.
36. Yang L, Liu Y, Liu CX,. Metabolism and pharmacokinetics of ginsenosides. Asian J Pharmacodyn Pharmacokinet 2006; 6: 103-120.
37. Liu CX, Xiao PG,. Recent advances on ginseng research in China. J Ethnopharmacol 1992; 36: 27-38.
38. Sun LQ,. Information on research and application of Ginseng, the king of traditional and herbal medicines. Asian J Drug Metab Pharmacokinet 2004; 4: 264-282.
39. Gurley BJ, Gardner SF, Hubbard MA, et al,. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002; 72: 276-287.
40. Anderson GD, Rosito G, Mohustsy MA, Elmer GW,. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol 2003; 43: 643-648.
41. Liu Y, Zhang JW, Li W, et al,. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci 2006; 91: 356-364.
42. Wacher VJ, Silverman JA, Zhang Y, Benet LZ,. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998; 87: 1322-1330.
43. Sutherland L, Ebner T, Burchell B,. The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol 1993; 45: 295-301.
44. Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, Wrighton SA,. Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods 2000; 44: 313-324.
45. Bradshaw DM, Arceci RJ,. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 2000; 16: 3674-3690.